This direct effect of NCL-1 on HUVEC-C is an anti-angiogenic mechanism beyond the mechanism of conventional angiogenesis inhibitors such as bevacizumab, which just deplete tumor cell-derived VEGF, and might explain why we do not observe normalization of the vasculature upon NCL-1 treatment. This evidence concerns the gene CAPN3 and neoplasm.